Potentially inappropriate medications in older adults with heart failure: prevalence and predictors using the 2023 Beers Criteria

9 May 2026 (08:00 - 12:45)

Organised by:

Sign in to view the resources

About the speaker

Doctor Marwan Sheikh-Taha

Lebanese American University, Byblos Campus, Blat (Lebanon)

5 More presentations in this session

Presentation thumbnail

Association of poor adherence to guideline-directed medical treatment with adverse events including fatal arrhythmia in heart failure with reduced ejection fraction: A nationwide cohort analysis

Doctor M. Kim (Goyang, KR)

Presentation thumbnail

Dapagliflozin in patients hospitalised with newly diagnosed heart failure: an analysis of the randomized DAPA ACT HF-TIMI 68 trial

Doctor P. Haller (Vienna, AT)

Presentation thumbnail

Impact of LVEF and de novo heart failure on outcomes of SGLT2 inhibitor therapy initiated during acute heart failure

Doctor A. Castro Pinto (Guimaraes, PT)

Presentation thumbnail

The O-GlcNAcase inhibitor ASN90 opposes acute cardiac decompensation in rats with chronic heart failure.

Doctor G. Vincent (Rouen, FR)

Presentation thumbnail

Impact of Dapaglizofin on right ventricular function and pulmonary pressure: a secondary analysis of the RIVED registry

Associate Professor A. Palazzuoli (Siena, IT)

Access the full session

Session thumbnail

Medical treatment in acute heart failure

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026

You may be interested in

Congress Session

Acute heart failure therapies: from clinical trials to clinical practice

Congress Session

Devices in acute heart failure

Congress Session

Guideline-directed medical therapy implementation in special clinical scenarios

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources